Pfizer's Eucrisa Proves Safety In Kids With Atopic Dermatitis
Zacks Investment Research | Jul 02, 2019 04:56AM ET
Pfizer Inc. (NYSE:PFE) announced top-line results from a late-stage study, which evaluated its PDE4 inhibitor, Eucrisa (crisaborole ointment, 2%), for the treatment of mild to moderate atopic dermatitis (AD) or eczmema in children aged three months to two years.
The steroid-free topical treatment is already approved for eczema in patients aged two years and older in the United States and Canada. The drug is also marketed in Israel and Australia under the brand name Staquis for the given patient population.
The phase IV CrisADe CARE 1 study showed that Eucrisa was well-tolerated over a four- week regimen and its safety profile was consistent with the previous clinical studies. Pfizer plans to present detail results from this label expansion study at an upcoming scientific conference.
Shares of Pfizer have inched up 0.3% so far this year, underperforming the industry’s rise of 2.1%.
We would like to remind investors that Pfizer added Eucrisa to its portfolio with the acquisition of Anacor Pharmaceuticals in June 2016. The company estimates Eucrisa’s peak sales potential to be at least $2 billion.
Another interesting eczema candidate in Pfizer’s portfolio is its investigational JAK1 inhibitor, abrocitinib. In May this year, the company announced that a pivotal late-stage study evaluating abrocitinib for the treatment of moderate-to-severe AD, met all the co-primary and secondary endpoints.
The phase III program (B7451012) examined two doses (100mg and 200mg once daily) of abrocitinib (PF-04965842) monotherapy in patients aged 12 and above for over 12 weeks.
Notably, many companies are developing medicines to address AD/eczema. A key new entrant in the AD market is Sanofi (NASDAQ:SNY) /Regeneron Pharmaceuticals’ (NASDAQ:REGN) Dupixent. Others also developing key immunology candidates in late-stage studies for AD include AbbVie (NYSE:ABBV) (upadacitinib) and Lilly (NYSE:LLY) (Olumiant).
Zacks Rank
Pfizer currently carries a Zacks Rank #3 (Hold). You can see .
This Could Be the Fastest Way to Grow Wealth in 2019
Research indicates one sector is poised to deliver a crop of the best-performing stocks you'll find anywhere in the market. Breaking news in this space frequently creates quick double- and triple-digit profit opportunities.
These companies are changing the world – and owning their stocks could transform your portfolio in 2019 and beyond. Recent trades from this sector have generated +98%, +119% and +164% gains in as little as 1 month.
Get The News You Want
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.